A team of bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) — a potent immune-boosting protein that holds promise for cancer treatment — loses effectiveness over time when used as an immunotherapeutic. The research challenges long-held assumptions about IL-12 s behavior in the body and offers a path toward safer and more effective dosing regimens.